Wall Street analysts expect that Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) will post ($0.81) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Eyegate Pharmaceuticals’ earnings. Eyegate Pharmaceuticals reported earnings per share of ($0.75) during the same quarter last year, which would suggest a negative year-over-year growth rate of 8%. The company is expected to announce its next earnings report on Friday, March 6th.
According to Zacks, analysts expect that Eyegate Pharmaceuticals will report full-year earnings of ($2.09) per share for the current financial year. For the next fiscal year, analysts anticipate that the business will post earnings of ($2.67) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Eyegate Pharmaceuticals.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last announced its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.40).
Separately, ValuEngine upgraded Eyegate Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, January 13th.
A hedge fund recently bought a new stake in Eyegate Pharmaceuticals stock. Virtu Financial LLC bought a new stake in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 12,913 shares of the specialty pharmaceutical company’s stock, valued at approximately $129,000. Virtu Financial LLC owned about 0.32% of Eyegate Pharmaceuticals as of its most recent filing with the SEC. 44.58% of the stock is currently owned by institutional investors.
Shares of NASDAQ:EYEG opened at $6.10 on Tuesday. The business’s fifty day moving average price is $7.58 and its two-hundred day moving average price is $4.35. The stock has a market cap of $25.47 million, a PE ratio of -2.60 and a beta of 2.68. Eyegate Pharmaceuticals has a one year low of $2.25 and a one year high of $12.89.
About Eyegate Pharmaceuticals
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Featured Story: What are gap-down stocks?
Get a free copy of the Zacks research report on Eyegate Pharmaceuticals (EYEG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyegate Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
